SOLIGENIX, INC. 8-K

What Happened
On April 28, 2026, Soligenix, Inc. (SNGX) announced via an 8-K press release that the Data Monitoring Committee (DMC) recommended halting the Phase 3 FLASH2 (Fluorescent Light Activated Synthetic Hypericin 2) trial for futility. The trial was testing HyBryte™ (Synthetic Hypericin) for the treatment of cutaneous T‑cell lymphoma (CTCL). The company said it will evaluate strategic options going forward, including potential merger and acquisition opportunities and the possibility of advancing dusquetide for the treatment of Behçet’s Disease. The press release is filed as Exhibit 99.1 to the Form 8-K.

Key Details

• Filing date: April 28, 2026 (Form 8-K, Item 8.01; press release Exhibit 99.1).
• Trial: Phase 3 FLASH2 evaluating HyBryte™ (Synthetic Hypericin) for cutaneous T‑cell lymphoma.
• DMC action: Interim efficacy analysis recommended stopping the study for futility.
• Next steps: Company will evaluate strategic alternatives, including M&A and potential development of dusquetide for Behçet’s Disease.

Why It Matters
The DMC’s recommendation to stop the pivotal Phase 3 trial for futility ends this specific development path for HyBryte in CTCL and shifts the company’s immediate priorities. Management’s stated focus on evaluating strategic alternatives and other programs (like dusquetide) signals a potential change in corporate strategy that investors should monitor through further filings and announcements. The company’s 8-K also includes the standard forward‑looking statements caution about risks and uncertainties.